mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation.

Aging is associated with an increased incidence of venous thromboembolism (VTE), resulting in significant morbidity and mortality in the elderly. Platelet hyperactivation is linked to aging-related VTE. However, the mechanisms through which aging enhances platelet activation and susceptibility to VTE are poorly understood. In this study, we demonstrated that mechanistic target of rapamycin complex 1 (mTORC1) signaling is essential for aging-related platelet hyperactivation and VTE. mTORC1 was hyperactivated in platelets and megakaryocytes (MKs) from aged mice, accompanied by elevated mean platelet volume (MPV) and platelet activation. Inhibition of mTORC1 with rapamycin led to a significant reduction in susceptibility to experimental deep vein thrombosis (DVT) in aged mice (P < .01). To ascertain the specific role of platelet mTORC1 activation in DVT, we generated mice with conditional ablation of the mTORC1-specific component gene Raptor in MKs and platelets (Raptor knockout). These mice developed markedly smaller and lighter thrombi, compared with wild-type littermates (P < .01) in experimental DVT. Mechanistically, increased reactive oxygen species (ROS) production with aging induced activation of mTORC1 in MKs and platelets, which, in turn, enhanced bone marrow MK size, MPV, and platelet activation to promote aging-related VTE. ROS scavenger administration induced a significant decrease (P < .05) in MK size, MPV, and platelet activation in aged mice. Our findings collectively demonstrate that mTORC1 contributes to enhanced venous thrombotic susceptibility in aged mice via elevation of platelet size and activation.

[1]  J. Hoffmann,et al.  Effect of age on mean platelet volume: Does it exist? , 2015, Experimental Gerontology.

[2]  A. Franco,et al.  Platelets at the interface of thrombosis, inflammation, and cancer. , 2015, Blood.

[3]  Anindya Gupta.  Factor XI antisense oligonucleotide for venous thrombosis. , 2015, New England Journal of Medicine.

[4]  E. Hylek,et al.  Age-Related Changes in Thrombosis and Hemostasis , 2014, Seminars in Thrombosis & Hemostasis.

[5]  Michael N. Hall,et al.  Making new contacts: the mTOR network in metabolism and signalling crosstalk , 2014, Nature Reviews Molecular Cell Biology.

[6]  J. Ware,et al.  Platelet function beyond hemostasis and thrombosis , 2013, Current opinion in hematology.

[7]  I. T. Ten Berge,et al.  Treatment with everolimus is associated with a procoagulant state. , 2013, Thrombosis research.

[8]  H. Fuchs,et al.  Rapamycin extends murine lifespan but has limited effects on aging. , 2013, The Journal of clinical investigation.

[9]  V. Chopra,et al.  Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis , 2013, The Lancet.

[10]  O. Uslukaya,et al.  Can Mean Platelet Volume be a New Risk Factor in Portal Venous Thrombosis? , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[11]  G. Salido,et al.  Long-term mTOR inhibitors administration evokes altered calcium homeostasis and platelet dysfunction in kidney transplant patients , 2013, Journal of cellular and molecular medicine.

[12]  A. Chauhan,et al.  Hydrogen Peroxide Promotes Aging-Related Platelet Hyperactivation and Thrombosis , 2013, Circulation.

[13]  Lan Ye,et al.  Rapalogs and mTOR inhibitors as anti-aging therapeutics. , 2013, The Journal of clinical investigation.

[14]  V. Čulić.  Aspirin for preventing venous thromboembolism. , 2013, The New England journal of medicine.

[15]  K. Paraskevas.  Aspirin for preventing venous thromboembolism. , 2013, New England Journal of Medicine.

[16]  D. Habart,et al.  Conditional Knockout of Integrin α2β1 in Murine Megakaryocytes Leads to Reduced Mean Platelet Volume , 2013, PloS one.

[17]  P. Rabinovitch,et al.  mTOR is a key modulator of ageing and age-related disease , 2013, Nature.

[18]  C. Beyan.  Is Mean Platelet Volume a Predictive Marker in Patients With Venous Thrombosis? , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[19]  F. Lehner,et al.  A Randomized, Controlled Study to Assess the Conversion From Calcineurin‐Inhibitors to Everolimus After Liver Transplantation—PROTECT , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  M. Kayan,et al.  Mean Platelet Volume Is Increased in Patients With Deep Vein Thrombosis , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[21]  G. Lippi,et al.  Mean platelet volume increases with aging in a large population study. , 2012, Thrombosis research.

[22]  A. Ipek,et al.  Platelet Activity Indices in Patients With Deep Vein Thrombosis , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[23]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[24]  F. Violi,et al.  Platelet oxidative stress and thrombosis. , 2012, Thrombosis research.

[25]  O. McCarty,et al.  S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. , 2011, Blood.

[26]  J. Loscalzo,et al.  Glutathione Peroxidase-3 Deficiency Promotes Platelet-Dependent Thrombosis In Vivo , 2011, Circulation.

[27]  L. Rimsza,et al.  Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. , 2011, Blood.

[28]  J. Sluijter,et al.  MicroRNA-100 Regulates Neovascularization by Suppression of Mammalian Target of Rapamycin in Endothelial and Vascular Smooth Muscle Cells , 2011, Circulation.

[29]  X. Bai,et al.  Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. , 2010, Cellular signalling.

[30]  C. Beyan,et al.  The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases , 2010, International journal of clinical practice.

[31]  D. Usero,et al.  Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation. , 2010, Transplantation proceedings.

[32]  Deepak L. Bhatt,et al.  Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[33]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[34]  L. Barrera,et al.  Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation. , 2009, Transplantation Proceedings.

[35]  M. Blagosklonny,et al.  Aging: ROS or TOR , 2008, Cell cycle.

[36]  A. Weyrich,et al.  mTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. , 2007, Blood.

[37]  W. Vainchenker,et al.  Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. , 2006, Blood.

[38]  E. Coban,et al.  The mean platelet volume in patients with obesity , 2005, International journal of clinical practice.

[39]  G. Schmid,et al.  Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. , 2005, Blood.

[40]  D. Sane,et al.  Aging and Thrombosis , 2002, Seminars in thrombosis and hemostasis.

[41]  A. Takeshita,et al.  Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. , 1999, Circulation research.

[42]  AkiraTakeshita,et al.  Mitochondrial Electron Transport Complex I Is a Potential Source of Oxygen Free Radicals in the Failing Myocardium , 1999 .

[43]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[44]  J. Loscalzo,et al.  Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. , 1996, The Journal of clinical investigation.

[45]  R. Wiesner,et al.  The use of sirolimus should be restricted in liver transplantation. , 2012, Journal of hepatology.

[46]  T. Wakefield,et al.  Aging is associated with impaired thrombus resolution in a mouse model of stasis induced thrombosis. , 2010, Thrombosis Research.

[47]  X. Bai,et al.  Key factors in mTOR regulation , 2009, Cellular and Molecular Life Sciences.

[48]  M. Berndt,et al.  Platelet physiology and thrombosis. , 2004, Thrombosis research.

[49]  Thompson Cb,et al.  From precursor to product: how do megakaryocytes produce platelets? , 1986, Progress in clinical and biological research.